Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder
Authors:
- 1 October 2000
- journal article
- review article
- Published by Wiley in The Prostate
- Vol. 45 (2) , 184-193
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working GroupJournal of Clinical Oncology, 1999
- Health-Related Quality of Life in Men With Metastatic Prostate Cancer Treated With Prednisone Alone or Mitoxantrone and PrednisoneJournal of Clinical Oncology, 1999
- Prognostic Significance of Extent of Disease in Bone in Patients With Androgen-Independent Prostate CancerJournal of Clinical Oncology, 1999
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Journal of Clinical Oncology, 1996
- Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?Journal of Clinical Oncology, 1985
- A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.Journal of Clinical Oncology, 1985
- Phase II Trial of Doxorubicin in Bidimensionally Measurable Prostatic AdenocarcinomaJournal of Urology, 1984
- Treatment response criteria for prostatic cancerThe Prostate, 1984
- Weekly doxorubicin in endocrine-refractory carcinoma of the prostate.Journal of Clinical Oncology, 1983
- A Comparison of Hydroxyurea, Methyl-chloroethyl-cyclohexy-nitrosourea and Cyclophosphamide in Patients With Advanced Carcinoma of the ProstateJournal of Urology, 1981